Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by NewEdge Wealth LLC

NewEdge Wealth LLC lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 40,765 shares of the biopharmaceutical company’s stock after buying an additional 3,636 shares during the period. NewEdge Wealth LLC’s holdings in Regeneron Pharmaceuticals were worth $29,038,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of REGN. Rakuten Securities Inc. boosted its holdings in Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 19 shares during the period. FSA Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $26,000. Fairfield Financial Advisors LTD acquired a new position in shares of Regeneron Pharmaceuticals during the third quarter worth $37,000. Truvestments Capital LLC purchased a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at about $39,000. Finally, Valley Wealth Managers Inc. purchased a new position in Regeneron Pharmaceuticals in the third quarter valued at about $49,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $706.94 on Thursday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $642.00 and a twelve month high of $1,211.20. The stock has a market cap of $77.29 billion, a PE ratio of 18.47, a price-to-earnings-growth ratio of 2.34 and a beta of 0.08. The business’s 50 day moving average is $698.68 and its 200-day moving average is $874.30. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same period last year, the company earned $11.86 earnings per share. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. On average, analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.50%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 2.30%.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Canaccord Genuity Group started coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. Royal Bank of Canada dropped their target price on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. Wells Fargo & Company reduced their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research report on Friday, January 10th. Leerink Partners raised Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $762.00 to $834.00 in a report on Wednesday, February 5th. Finally, Leerink Partnrs raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.